2026-10-14T07:45:23Z https://api.figshare.com/v2/oai

oai:figshare.com:article/33770803 2026-09-15T04:27:50Z category_363 portal_316 item_type_3 month_year_09_2026

Supplementary file 1_Comparative efficacy of AAC and ibuprofen versus lasmiditan, ubrogepant, and rimegepant for the acute treatment of episodic migraine in adults: a systematic review and network meta-analysis.docx Ashoke Mitra (24911974) Billy Franks (592009) Richard Petruschke (24911977) Abhijeet Dhiman (9143229) Nitu Bansal (15010236) Neurology and Neuromuscular Diseases migraine network meta-analysis over-the-counter pain relief prescription drugs Background<p>A range of pharmacologic options is available for acute migraine treatment, yet the efficacy and safety of commonly used over-the-counter (OTC) therapies relative to newer prescription agents remain unclear. Given the scarcity of direct head-to-head trials, this network meta-analysis (NMA) of randomized controlled trials (RCTs) evaluated selected OTC therapies against newer oral agents, including CGRP antagonists and the 5-HT₁F receptor agonist.</p>Methods<p>A comprehensive literature search was conducted in PubMed, Embase, and CENTRAL for RCTs of acute migraine therapies published between January 1990 and July 2025. Primary outcomes were 2-h (2 h) pain relief and pain freedom; secondary outcomes included 2-h photophobia, phonophobia and nausea. Effect sizes were calculated as relative risks (RRs) with 95% confidence intervals (CIs). A frequentist NMA was conducted to estimate comparative efficacy and safety across the treatment network.</p>Results<p>This NMA synthesized evidence from 25 RCTs, including 5 different interventions across 19 dose categories, involving a total of 22,100 participants with migraine. Compared with placebo, acetaminophen, aspirin, and caffeine (AAC) combination showed superior 2 h pain relief (RR, 1.76; 95% CI, 1.61–1.94; p-score = 0.96), followed by ibuprofen 400 mg and 200 mg. For 2 h pain freedom, AAC, ibuprofen 400 mg, and lasmiditan 200 mg showed broadly comparable favorable effects versus placebo, with similar RRs and p-scores. AAC also produced the greatest reductions in photophobia and phonophobia at 2 h (photophobia: RR, 1.99; 95% CI, 1.62–2.45; p-score = 0.97; phonophobia: RR, 1.53; 95% CI, 1.28–1.84; p-score = 0.89), while ibuprofen Liquigel 400 mg provided additional meaningful benefit. For nausea, rimegepant 75 mg demonstrated the strongest effect (RR, 1.15; 95% CI, 1.08–1.22; p-score = 0.85), followed by ibuprofen Liquigel 400 mg and AAC.</p>Conclusion<p>In this NMA, OTC therapies showed meaningful efficacy and favorable safety for acute episodic migraine versus placebo, with ibuprofen and AAC demonstrating consistent benefits across 2 h pain and secondary outcomes. These findings support their use as effective, accessible options alongside newer oral agents. Larger trials and patient-level analyses are needed to refine efficacy, optimize dosing, and personalize migraine management.</p>Systematic review registration<p>https://www.crd.york.ac.uk/PROSPERO/view/CRD420261325571, Identifier CRD420261325571.</p> 2026-09-15T04:27:50Z Dataset Dataset 10.3389/fneur.2026.1884713.s001 https://figshare.com/articles/dataset/Supplementary_file_1_Comparative_efficacy_of_AAC_and_ibuprofen_versus_lasmiditan_ubrogepant_and_rimegepant_for_the_acute_treatment_of_episodic_migraine_in_adults_a_systematic_review_and_network_meta-analysis_docx/33770803 CC BY 4.0